Intravenous immunoglobulin therapy for scleromyxedema: A case report and review of literature

Journal of Drugs in Dermatology

Volumn 9, Issue 3, 2010, Pages 263-265

  Sroa, Novie ^a   Campbell, Shannon ^b   Bechtel, Mark ^b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC HYDROXIDE; IMMUNOGLOBULIN; IMMUNOGLOBULIN KAPPA CHAIN; METHOTREXATE; MUCIN;

ABSENCE OF SIDE EFFECTS; ADULT; ARM; ARTICLE; BACK; CASE REPORT; CHEEK; DERMIS; DRUG MEGADOSE; DYSESTHESIA; DYSPHAGIA; ERYTHEMA; FIBROBLAST; FINGER; FOLLOW UP; FOREHEAD; HUMAN; IMMUNOTHERAPY; MAINTENANCE THERAPY; MALE; MOUTH; NECK; PROTEIN ELECTROPHORESIS; PRURITUS; RANGE OF MOTION; SCLEROMYXEDEMA; SKIN BIOPSY; SKIN FIBROSIS; SKIN TIGHTNESS; WEIGHT REDUCTION; REVIEW;

ADULT; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; SCLEROMYXEDEMA;

EID: 77950886441     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Wojas-Pelc A, Błaszczyk M, Glinska M, et al. Tumorous variant of scleromyxedema. Successful therapy with intravenous immunoglobulins. J Eur Acad Dermatol Venereol. 2005;19(4):462-465. (Pubitemid 40946101)
2. Blum M, Wigley FM, Hummers LK. Scleromyxedema: A case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine (Baltimore). 2008;87(1):10-20.
3. Lister RK, Jolles S, Whittaker S, et al. Scleromyxedema: Response to high-dose intravenous immunoglobulin (hdIVIg). J Am Acad Dermatol. 2000;43(2 Pt 2):403-408. (Pubitemid 30636551)
4. Körber A, Franckson T, Grabbe S, et al. Successful therapy of scleromyxoedema Arndt-Gottron with low-dose intravenous immunoglobulin. J Eur Acad Dermatol Venereol. 2007;21(4):553-554. (Pubitemid 46454922)
5. Gholam P, Hartmann M, Enk A Arndt-Gottron scleromyxoedema: Successful therapy with intravenous immunoglobulins. Br J Dermatol. 2007;157(5):1058-1060. (Pubitemid 47583517)
6. Efthimiou P, Blanco M. Intravenous gammaglobulin and thalidomide may be an effective therapeutic combination in refractory scleromyxedema: Case report and discussion of the literature. Semin Arthritis Rheum. 2008;38(3):188-194.
7. Dinneen AM, Dicken CH. Scleromyxedema. J Am Acad Dermatol. 1995;33(1):37-43.
8. Chanda JJ. Scleromyxedema. Cutis. 1979;24(5):549-552. (Pubitemid 10211386)
9. Farr PM, Ive Fa. PUVA treatment of scleromyxedema. Br J Dermatol. 1984;110(3):347-350.
10. Binitha MP, Nandakumar G, Thomas D. Suspected cardiac toxicity to intravenous immunoglobulin used for treatment of scleromyxedema. Indian J Dermatol Venereol Leprol. 2008;74(3):248-250. (Pubitemid 351918881)
11. Shergill B, Orteu CH, McBride SR, et al. Dementia associated with scleromyxoedema reversed by high-dose intravenous immunoglobulin. Br J Dermatol. 2005;153(3):650-652. (Pubitemid 41248229)
12. Rey JB, Luria RB. Treatment of scleromyxedema and the dermatoneuro syndrome with intravenous immunoglobulin. J Am Acad Dermatol. 2009;60(6):1037-1041.
13. Kulczycki A, Nelson M, Eisen A, et al. Scleromyxoedema: treatment of cutaneous and systemic manifestations with high-dose intravenous immunoglobulin. Br J Dermatol. 2003;149(6):1276-1281. (Pubitemid 38058107)
14. Wetter DA, Davis MD, Yiannias JA. Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: A retrospective review of Mayo Clinic experience. Mayo Clin Proc. 2005;80(1):41-47. (Pubitemid 40075990)
15. Righi A, Schiavon F, Jablonska S, et al. Intravenous immunoglobulins control scleromyxoedema. Ann Rheum Dis. 2002;61(1):59-61. (Pubitemid 34074842)
16. Kumar N, Rodriguez M. Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a. Mult Scler. 2004;10(1):85-86. (Pubitemid 38100532)
17. Karim A, Lawlor F, Black MM. Successful treatment of scleromyxoedema with high dose intravenous immunoglobulin. Clin Exp Dermatol. 2004;29(3):317-318. (Pubitemid 38658484)